Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations
人类肠道微生物组和美国人群的糖尿病风险
基本信息
- 批准号:10094713
- 负责人:
- 金额:$ 66.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-19 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdultAgeAnimal ExperimentsAnimal FeedAnimalsBacteriaBile AcidsBioinformaticsBiologicalBiological MarkersBiometryBranched-Chain Amino AcidsButyratesCholineClassificationClinicalCoffeeCollaborationsCross-Sectional StudiesDataDemographic FactorsDevelopmentDiabetes MellitusDiabetes preventionDietDietary FiberEffectiveness of InterventionsEndocrine GlandsEnsureEnzymesEpidemiologyEthnic OriginEtiologyGenderGene ExpressionGene FamilyGenetic TranscriptionHealthHealthcareHispanic Community Health Study/Study of LatinosHumanIncidenceInflammationInfrastructureInstitutionIntakeInterventionLevocarnitineLife StyleLinkLongitudinal StudiesMeasuresMeatMedical HistoryMedicineMetabolicMetabolic DiseasesMetabolismMetagenomicsMethodsMicrobeMicrobiologyNon-Insulin-Dependent Diabetes MellitusNurses&apos Health StudyPathway AnalysisPathway interactionsPatternPharmaceutical PreparationsPhysical activityPhysiological ProcessesPlantsPlayPopulationPreparationPrevalencePreventionPrevention strategyProcessProspective StudiesPublic Health SchoolsQiResearchResearch DesignResearch PersonnelResourcesRiskRoleSample SizeSamplingStudy of LatinosSupervisionTaxonomyThe SunWeight maintenance regimenWomanbasecase controlcohortcollegecostdiabetes managementdiabetes riskdietaryenergy balanceenzyme pathwayexperiencefecal metabolomefollow-upfrontierfruits and vegetablesglucose metabolismgut microbiomegut microbiotahigh riskimprovedindividual variationindividualized preventionmenmetabolomicsmetatranscriptomicsmicrobialmicrobiomemicrobiome researchmicrobiotamicrobiota metabolitesmultiple omicsmutualismnew technologynovelpersonalized approachpersonalized strategiespolyphenolpreventive interventionprospectivesocioeconomicstrimethyloxamine
项目摘要
Project Summary/Abstract
Human gut microbiota, with its massive catalytical capacity and functional potential, may act as an “endocrine
organ” and significantly contribute to metabolic health. Indeed, basic microbiological research and culture-
based human studies have elucidated multiple pathways through which human gut microbiota may modulate
the risk of developing metabolic diseases, such as type 2 diabetes (T2D). Existing human studies also
demonstrated promising evidence supporting a link between microbiome and prevalent diabetes, although few
longitudinal studies have been conducted to establish a prospective relationship between microbiome and the
risk of developing T2D. This proposal represents major research efforts to significantly accelerate the
advances in the research of microbiome and T2D risk by examining prospective relationships between gut
microbial composition, functional potential, and fecal metabolome that operate in candidate pathways and T2D
risk. We will also use network analysis and other advanced methods to interrogate the overall metagenomic,
metatranscriptomic, and metabolomic profiles in fecal samples for the identification of novel microbial features
(i.e., microbes, their functional potential, gene transcription levels, and microbiota metabolites) and pathways
that might be involved in the development of T2D. As a secondary aim, we will evaluate the interplay between
diet and microbiome on fecal metabolome and T2D risk. Furthermore, these complementary, inter-connected
study aims will be realized by an experienced investigator team consisting of researchers with expertise in
microbiome, metabolomics, biomarker research, diabetes epidemiology, biostatistics, and bioinformatics. To
facilitate better generalizability and internal validity of research findings, we will examine these novel
associations in two US cohorts with complementary ethnic and socioeconomic profiles: Nurses’ Health Study II
and Hispanic Community Health Study / Study of Latinos. Rich resources of these two cohorts, including fecal
samples, repeated assessments of diet, lifestyle, medical history, and use of medications, longitudinal follow-
up on diabetes status, and infrastructure for sample preparation/storage and computing, will empower the
investigators to accomplish the proposed aims cost-effectively. To strengthen between-institution collaboration
and ensure a successful implementation of the proposed research, Drs. Qi Sun (at Harvard T.H. Chan School
of Public Health) and Qibin Qi (at Albert Einstein College of Medicine) will share the responsibility of
overseeing the overall conduct of research through the Multiple PI mechanism. In summary, this project will
elucidate prospective associations of gut microbiome and fecal metabolome with T2D risk and facilitate
discoveries of novel microbial features relevant to T2D risk. As such, the proposed research has a great
potential to identify novel microbiota-related risk or beneficial factors for developing more targeted and
individualized strategies for the prevention and management of diabetes.
项目摘要/摘要
人类肠道菌群具有巨大的催化能力和功能潜力,可能充当“内分泌
器官”并显着促进了代谢健康。的确,基本的微生物研究和培养 -
基于人类的研究已经阐明了人类肠道菌群可能调节的多种途径
患有代谢疾病的风险,例如2型糖尿病(T2D)。现有的人类研究
证明了有希望的证据,支持微生物组与普遍糖尿病之间的联系,尽管很少
已经进行了纵向研究,以建立微生物组与
发展T2D的风险。该提案代表着重大加速的主要研究工作
通过检查肠道之间的前瞻性关系,微生物组和T2D风险的研究进展
在候选途径和T2D中运行的微生物组成,功能潜力和粪便代谢组
风险。我们还将使用网络分析和其他高级方法来询问总体元基因组。
粪便样品中的元转录组和代谢组谱,用于鉴定新型微生物特征
(即微生物,其功能潜力,基因转录水平和微生物群代谢物)和途径
这可能参与了T2D的发展。作为次要目标,我们将评估
饮食和微生物组对粪便代谢组和T2D风险。此外,这些完整,相互连接
研究目标将由经验丰富的研究人员团队实现,该研究人员由具有专业知识的研究人员组成
微生物组,代谢组学,生物标志物研究,糖尿病流行病学,生物阶层和生物信息学。到
促进研究结果的更好的推广性和内部有效性,我们将研究这些新颖
美国两个人群的协会与完整的种族和社会经济概况:护士健康研究II
和西班牙裔社区健康研究 /拉丁裔研究。包括粪便在内的这两个队列的丰富资源
样本,对饮食,生活方式,病史的反复评估以及药物的使用,纵向跟随 -
提高糖尿病状态以及用于样本准备/存储和计算的基础架构,将授权
调查人员以成本有效的目标来完成拟议的目标。加强机构合作
并确保成功实施拟议的研究。 Qi Sun(在哈佛T.H. Chan学校
公共卫生)和Qibin Qi(位于爱因斯坦医学院的Albert Einstein学院)将分享
通过多个PI机制监督研究的总体进行。总而言之,这个项目将
阐明肠道微生物组和粪便代谢组与T2D风险的前瞻性关联并促进
与T2D风险相关的新型微生物特征的发现。因此,拟议的研究很棒
潜力识别与微生物群相关的新型风险或有益因素,以开发更多针对性和
预防和管理糖尿病的个性化策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qibin Qi其他文献
Qibin Qi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Qibin Qi', 18)}}的其他基金
Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations
人类肠道微生物组和美国人群的糖尿病风险
- 批准号:
10330542 - 财政年份:2021
- 资助金额:
$ 66.96万 - 项目类别:
Human Gut Microbiome and Incident Diabetes Risk in U.S. Populations
人类肠道微生物组和美国人群的糖尿病风险
- 批准号:
10547803 - 财政年份:2021
- 资助金额:
$ 66.96万 - 项目类别:
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes
糖尿病饮食、生活方式和肠道微生物群的代谢组学特征
- 批准号:
9900778 - 财政年份:2019
- 资助金额:
$ 66.96万 - 项目类别:
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes
糖尿病饮食、生活方式和肠道微生物群的代谢组学特征
- 批准号:
10381716 - 财政年份:2019
- 资助金额:
$ 66.96万 - 项目类别:
Metabolomics signatures underlying diet, lifestyle and gut microbiota for diabetes
糖尿病饮食、生活方式和肠道微生物群的代谢组学特征
- 批准号:
10115710 - 财政年份:2019
- 资助金额:
$ 66.96万 - 项目类别:
HIV Infection, Metabolites and Subclinical Atherosclerosis
HIV 感染、代谢物和亚临床动脉粥样硬化
- 批准号:
9272929 - 财政年份:2015
- 资助金额:
$ 66.96万 - 项目类别:
HIV Infection, Metabolites and Subclinical Atherosclerosis
HIV 感染、代谢物和亚临床动脉粥样硬化
- 批准号:
9120269 - 财政年份:2015
- 资助金额:
$ 66.96万 - 项目类别:
HIV Infection, Metabolites and Subclinical Atherosclerosis
HIV 感染、代谢物和亚临床动脉粥样硬化
- 批准号:
8993153 - 财政年份:2015
- 资助金额:
$ 66.96万 - 项目类别:
相似国自然基金
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
- 批准号:82302025
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
- 批准号:82302311
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Mitochondrial electron transport dysfunction: Dissecting pathomechanisms
线粒体电子传递功能障碍:剖析病理机制
- 批准号:
10679988 - 财政年份:2023
- 资助金额:
$ 66.96万 - 项目类别:
Exploring regulatory mechanisms of glyoxalase-1
探索乙二醛酶-1的调控机制
- 批准号:
10646721 - 财政年份:2023
- 资助金额:
$ 66.96万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10818835 - 财政年份:2023
- 资助金额:
$ 66.96万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10573109 - 财政年份:2023
- 资助金额:
$ 66.96万 - 项目类别:
Role of mitochondrial GDAP1 in Alzheimer's disease
线粒体 GDAP1 在阿尔茨海默病中的作用
- 批准号:
10739858 - 财政年份:2023
- 资助金额:
$ 66.96万 - 项目类别: